RF
RXRX icon

Rossby Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Rossby Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,000
Closed -$219K – 1862
2025
Q3 		$219K Buy
43,000
+15,000
+54% +$78.8K 0.07% 260
2025
Q2 		$142K Buy
+28,000
New +$138K 0.05% 315

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Rossby Financial's RXRX Position: Q4 2025 in Review

Rossby Financial sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 43,000 shares — an estimated $219K sold.

Rossby Financial first reported a position in RXRX in Q2 2025 and held it in 2 quarters. The position peaked at $219K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Rossby Financial reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rossby Financial sold 43,000 Recursion Pharmaceuticals shares in Q4 2025, an estimated $219K.
  • Rossby Financial first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Rossby Financial's Recursion Pharmaceuticals position peaked at $219K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Rossby Financial's 13F filing for Q4 2025, filed 12 Feb 2026.